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Parkinson’s disease (PD) is associated with diverse genetic and environmental susceptibilities. Functional
connections between PD genes have remained elusive. In this issue of Neuron, MacLeod et al. (2013) link
three PD susceptibility genes, LRRK2, PARK16, and VSP35, to a common cellular pathway and show how
these deficits contribute to dysfunction.Parkinson’s disease (PD) is the second
most common neurodegenerative dis-
order, affecting seven to ten million
people worldwide. Classic motor features
of PD consist of resting tremor, bradyki-
nesia, rigidity, and postural instability
that are caused by the selective degener-
ation of nigral-striatal dopaminergic
neurons. A pathological hallmark of PD
is the presence of Lewy bodies, which
are protein aggregates that accumulate
in affected brain regions (Goedert et al.,
2012). PD is a mostly sporadic disease,
but rare inherited forms of PD offer clues
to possible underlying genetic factors
and mechanisms that might also be rele-
vant to sporadic PD. The discovery in
1997 of mutations in the alpha-synuclein
gene (SNCA) as a cause of PD was signif-
icant not only because it was the first gene
associated with PD, but also because
alpha synuclein protein was found to be
the main building block of Lewy bodies
(Lee and Trojanowski, 2006).
After alpha-synuclein, mutations in
several additional genes (DJ-1, LRRK2,
PARKIN, PINK1, ATP13A2, VPS35, and
EIF4G1) have been linked to familial PD
(Kumar et al., 2012). However, monogenic
causes account for only 3% of all PD
cases. Moreover, incomplete penetrance
within these families suggests additional
genetic risk factors and interactions
with the environment are crucial for devel-
oping disease. Genome-wide association
studies (GWASs) are a powerful tool for
defining common genetic variants that
are associated with increased risk of
disease. Several recent PD GWASs and
meta-analyses have facilitated the identi-fication of further genetic risk factors
for sporadic disease. Each successive
GWAS presents a list of risk loci, some
of which overlap with prior studies and
others of which fail to replicate (Lill et al.,
2012).
The identification of key Mendelian
genes in familial PD and an explosion of
new susceptibility loci associated with
sporadic PD presents a critical question:
do the genes associated with PD interact
with each other or rather do each of them
function independently but ultimately
converge in a common pathological
outcome—dopaminergic neuron loss
and resulting parkinsonism? Accruing
evidence points to genetic interactions
between some of the rare familial PD
genes (e.g., parkin and pink1; Clark
et al., 2006; Park et al., 2006) and poten-
tial functional associations between
some other PD genetic contributors
(e.g., PARK9 and alpha-synuclein; Gitler
et al., 2009; LRRK2 and parkin; Smith
et al., 2005; and glucocerebrosidase and
alpha-synuclein; Mazzulli et al., 2011).
However, interactions between genes
associated with the more common
sporadic PD remain unclear.
The study by MacLeod et al. (2013)
starts out by tackling this problem in an
elegant way. They begin their analysis on
common variants at seven genetic loci
that have been associated by GWAS
with increased PD risk in diverse patient
populations: SNCA, LRRK2, MAPT,
HLA-DRA, PARK16, LAMP3, and STK39.
They used as a tractable readout changes
in brain gene expression profiles corre-
lated with the presence or absence ofNeuron 77a given PD risk allele. Importantly, they
focused their analysis on brain tissue
from unaffected individuals, in order to
avoid confounding effects on gene
expression owing to disease progression
and neuron loss. They scoured publically
available transcriptome data sets for
common effects on gene expression
signatures associated with the presence
or absence of PD risk alleles. Of the seven
PD risk loci analyzed, the effects on gene
expression signatures by variants at the
PARK16 and LRRK2 loci were most
similar. With this clue in hand, they
proceed to reanalyze existing GWAS
data sets and uncover remarkably strong
evidence for a genetic interaction
between LRRK2 and PARK16. They find
that the effect of an LRRK2 variant on
PD risk strongly modifies the effects of
a risk variant at the PARK16 locus and
vice versa. Thus, two common variants
associated with sporadic PD seem to
interact genetically.
OnceMacLeod et al. (2013) established
genetic interaction between LRRK2 and
PARK16, they next set out to define
whether and how LRRK2 and PARK16
might functionally interact. LRRK2 has
been extensively studied and its cellular
functions and the effects of disease-asso-
ciated mutations are being unraveled
(Tsika and Moore, 2012). But much less
is known about PARK16. Moreover, the
PARK16 locus encompasses five candi-
date genes (SLC45A3, NUCKS, RAB7L1,
SLC41A1, and PM20D1). Which of these
is the key gene and how does it interact
with LRRK2? To answer this question,
MacLeod et al. (2013) systematically, February 6, 2013 ª2013 Elsevier Inc. 377
Neuron
Previewstested each of the five genes for the
ability to rescue a phenotype caused by
LRRK2 mutation. In primary rat neurons,
expressing a PD-linked mutant form of
LRRK2 (G2019S) causes a dramatic
reduction in neurite length. Overexpres-
sion of RAB7L1, but not the other four
PARK16 locus genes, was able to
suppress the mutant LRRK2-induced
neurite length phenotype. Next, MacLeod
et al. (2013) powerfully extend their find-
ings to an animal model and show that
upregulation of RAB7L1 rescues dopami-
nergic neuron loss and reduced lifespan
associated with LRRK2 mutation in
Drosophila, whereas dopamine neuron-
specific knockdown of RAB7L1 in flies
causes dopaminergic neuron degenera-
tion. Taken together, these data strongly
suggest that RAB7L1 functions in
a pathway with LRRK2.
RAB7L1 belongs to a family of small
GTPases that function in diverse aspects
of cell biology, including essential roles
as regulators of vesicular trafficking. Be-
yond the compelling genetic and cellular
evidence by MacLeod et al. (2013)
implicating RAB7L1, this gene was
a good candidate to consider because
of previous connections between Rabs,
vesicle trafficking, and PD (Gitler et al.,
2008). Having provided evidence that
alteration in RAB7L1 function is the
likely culprit responsible for the PARK16
locus association with PD risk, MacLeod
et al. (2013) next tried to figure out how
at the molecular level. In other words,
could they zoom in on the RAB7L1
gene and try and find a SNP associated
with PD risk and then figure out the
consequence of this SNP on RAB7L1
function? This type of analysis is exceed-
ingly challenging because of linkage
disequilibrium—for any given chromo-
somal region, many variants are often
closely associated. In the quagmire of
variants, how does one identify the
‘‘causal’’ SNP?
A breakthrough for MacLeod et al.
(2013) came when they explored a
recently compiled treasure trove of
genome-wide splicing data from human
lymphoblasts (Montgomery et al., 2010).
Remarkably, they found that the same
exact haplotype (a collection of variants
that are located closely together) at
PARK16 associated with PD risk was
also associated with alternative splicing378 Neuron 77, February 6, 2013 ª2013 Elseof RAB7L1. The PD risk allele was charac-
terized by the skipping of RAB7L1 exons 2
and 3 and the protective PARK16 allele
was associated with increased exon 2
inclusion in RAB7L1 mRNA. MacLeod
et al. (2013) report that skipping of
these exons is predicted to lead to a trun-
cated RAB7L1 protein lacking a critical
GTP-binding domain. Importantly, they
test this hypothesis in primary neurons
and in Drosophila and show that
this truncated protein, unlike wild-type
RAB7L1, is unable to protect against the
LRRK2 mutant phenotypes. Furthermore,
analysis of human brain tissue revealed a
significant reduction in full-length RAB7L1
protein in individuals harboring the
PARK16 risk allele compared to individ-
uals with the protective allele. Thus, using
a battery of genomic analyses coupled
with functional studies in cell cultures
and animal models, MacLeod et al.
(2013) provide us with a mechanistic
explanation for how variants in PARK16
increase risk for PD: by affecting splicing
of RAB7L1mRNA, levels of fully functional
RAB7L1 protein decrease.
MacLeod et al. (2013) turn their atten-
tion to elucidating first how LRRK2 and
RAB7L1 work together and, second, the
cellular consequences of defects in
this pathway. Previous data implicated
LRRK2 mutations in abnormal lysosomal
morphology and delivery of proteins to
the lysosome. Moreover, RAB7L1 local-
izes prominently to the Golgi and the
retromer complex plays a critical role in
protein sorting between lysosomes and
Golgi. Therefore, MacLeod et al. (2013)
hypothesized that the cellular defects
caused by mutant LRRK2 could be
caused, at least in part, by defects in the
retromer machinery. The retromer com-
plex was also probably on MacLeod
et al. (2013)’s radar because of the recent
identification by exome sequencing of
mutations in VPS35, a component of the
retromer complex, in some rare familial
forms of PD (Kumar et al., 2012). Again,
turning to mechanistic studies in primary
neurons and Drosophila, MacLeod et al.
(2013) provide further evidence linking
LRRK2, RAB7L1, and VPS35 in a func-
tional pathway. They show that VPS35
overexpression is able to rescue the neu-
rite length defects and dopaminergic
neuron loss caused by either expression
of mutant LRRK2 or knockdown ofvier Inc.RAB7L1. Moreover, expressing mutant
LRRK2 or knockdown of RAB7L1 in
neuronal cell lines or in mouse brain
caused a marked reduction in protein
levels of two components of the retromer
complex, VPS35 and VPS29. Finally,
in human PD brain, MacLeod et al.
(2013) observed a significant decrease in
VPS35 mRNA. Thus, it appears that defi-
cits in the LRRK2/RAB7L1 pathway may
lead to retromer complex dysfunction.
These deficits can be rescued by sup-
pressing retromer defects (for example,
by upregulation of VPS35).
This paper is an elegant example of
pursuing a PD genetic pathway using
a combination of state-of-the-art com-
putational and genomics approaches
with tried and true cell biological and
genetic model system approaches. In
one fell swoop, MacLeod et al. (2013)
have (1) provided compelling evidence
for RAB7L1 to be the key gene in the
PARK16 locus; (2) discovered a novel
functional interaction between RAB7L1
and the PD disease gene LRRK2; (3) con-
nected LRRK2 and RAB7L1 functionally
to another PD disease gene, VPS35; (4)
defined how SNPs in the PARK16 locus
associated with PD risk cause alterations
in RAB7L1 mRNA splicing, leading to
lower levels of RAB7L1 protein—pro-
viding a mechanism for how PARK16
variants can increase risk for disease;
and (5) showed that the high-risk common
variants at the PARK16 and LRRK2 loci
are dependent on one another. These
findings promise to not only have a
profound impact on our understanding
of PD mechanisms but also on how we
think about PD genetics and howwe inter-
pret genetic studies and utilize genomic
data sets in the future.
Technological innovations have spur-
red the study of PD genetics with
evolution from classic linkage analysis
for identifying Mendelian genes to
GWAS for defining common genetic vari-
ants associated with increased risk of
sporadic disease. Next generation ap-
proaches such as exome sequencing
and even whole-genome sequencing are
increasing in prevalence and promise to
help unravel even more of the PD genetic
landscape. While GWAS is a powerful
approach for identifying new genes and
loci associated with a diverse collection
of human diseases, a major challenge
Neuron
Previewswith GWAS has been its inability to trans-
late potential causal SNPs to under-
standing mechanistically how these vari-
ants confer risk. The approach taken by
MacLeod et al. (2013) offers us a lesson
on how functional studies in model
systems can be combined with unbiased
human genetics and genomics studies
to help elucidate novel genetic contribu-
tors to PD and many other human
diseases.
In parallel to the tremendous genetic
advances, there has been a recent
seismic shift in understanding of mecha-
nisms of PD initiation and progression.
Neuropathologists have long appreciated
that PD is characterized by widespread
changes, involving both the peripheral
and central nervous system (Braak et al.,
2003). Remarkably, alpha-synuclein, the
pathological substrate of Lewy bodies,
seems to be able to spread from neuron
to neuron and to propagate through-
out anatomically interconnected brain
regions. Indeed, a single injection of a
preparation of alpha-synuclein aggre-
gates into the mouse striatum is sufficient
to kick off an inexorable spread of PD-like
pathology and progressive loss of dopa-
minergic neurons, decreased dopamine
levels, and eventual motor impairments
(Luk et al., 2012). It is now clear that
alpha-synuclein spread is a critical aspect
in PD pathogenesis (Goedert et al., 2012).A challenge will now be to integrate the
genetic and pathological breakthroughs
in order to define how the genetic suscep-
tibility factors interface with alpha-synu-
clein spread. Do genetic loci linked to
PD increase risk of disease, at least in
part, by enhancing the initiation or
accelerating the spread of alpha-synu-
clein pathology? Although this study
focused on LRRK2 and PARK16, similar
approaches can be launched to analyze
potential interactions between other
genetic susceptibility factors, including
alpha-synuclein. One day, these parallel
approaches may converge on a common
pathway.
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Whether neurons generated in vitro from human embryonic stem cells (ESCs) or induced pluripotent stem
cells (iPSCs) have in vivo-like properties is unknown. In this issue of Neuron, Espuny-Camacho et al.
(2013) show that ESC-/iPSC-derived cortical neurons make specific projections and functional synapses
when transplanted into a neonatal mouse brain.Efforts to study the development of the
human cerebral cortex have been compli-
cated by the difficulty of obtaining humanfetal brain tissue. An attractive solution to
this problem is to use human embryonic
stem cells (ESCs) or induced pluripotentstem cells (iPSCs) to recapitulate human
brain development in vitro or in experi-
mental animals. Over the last decade,, February 6, 2013 ª2013 Elsevier Inc. 379
